The urokinase-type plasminogen activator (uPA) (1, 6± o,61ng/mL), II(3.04±1.03 ng/mL), III (10.53±7.1ng/mL) and IV (20.42±10.81ng/mL) (P< .0005, Spearman test 
HIV infection/AIDS is a global pandemic with cases reported from virtually every country. Approximately 40.000 individuals are newly infected each day 1 . Progression of HIV infection is largely dependent on the interaction between tha viral factors and host factors. HIV primarily infect cells which expressed CD4 receptor such as monocyte-macrophage, T lymphocyte, dendritic cell, langerhans and NK cell. 1, 2, 3, 4 It brings about the destruction of those cell through multiple mechanism including apoptosis. 5, 6, 7, 8, 9 The loss of CD4 cell population ultimately leads to the inability of infected persons to deal with opportunistic organism. 5, 6 The hallmark of HIV/AIDS infection is to identify immunodeficiency status (stage), because these stage will predict the progression of the HIV infection and treatment response. Imunodefficiency status may be measured through CD4 T lymphocyte count. 3, 4 Immune activation in HIV infection is known to be linked positively to HIV-1 replication and negatively to CD4 T-cell depletion. 5, 6, 7, 8 SuPAR is a component of the plasminogen activation system, which comprises urokinase-type plasminogen activator (uPA) and its receptor (uPAR). 10 uPAR is expressed on a variety of different immune cells such as macrophage, T lymphocyte, NK cells, dendritic cell and langerhans cells. 10, 11 suPAR is generated by either proteolytic cleavage or shedding from cells. 10, 11 SuPAR concentrations are increased and prognostic in a variety of inflammatory including HIV infection. 10 The blood level of the soluble urokinase-type plasminogen activator receptor (suPAR) is increased in untreated human immunodeficiency virus-1 (HIV-1) infection and decreases in HIV-1-infected patients after initiation of highly active antiretroviral therapy (HAART). 12, 13, 14, 15 The plasma concentration of soluble urokinase-type plasminogen activator receptor (suPAR, CD87) is a strong independent predictor of mortality in untreated patients with HIV-1 infection. 15 Plasma concentrations of this immune marker can be quickly and inexpensively measured using a simple enzyme-linked immunosorbent assay (ELISA), which requires much less sophisticated laboratory infrastructure than that needed for CD4 cell count or plasma viral load measurement. Such an assay might therefore be potentially useful in resource-limited settings. 15, 16 This study try to determine correlation of suPAR plasma consentration with CD4 T lymphocyte to identify immunodeficiency state of HIV/AIDS infection based on WHO 2006 criteria. 
Blood sampling
Two blood samples were drawn before treatment, CD4 counts were measuresed with an Epics XL-MCL Coulter flowcytometer. 17 EDTA plasma for suPAR measurement was stored at -80°C. Plasma suPAR concentrations were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) (suPARnostic,™ ViroGates, Lyngby, Denmark) following the manufacturer's instructions. This is a simple double monoclonal antibody sandwich assay that measures total suPAR, including both full-length and cleaved forms of the receptor. In brief, a standard control curve (range 0.6 -19.3 ng/ml), positive control, and test samples were incubated in duplicates in a 96-well plate pre-coated with anti-suPAR antibody. Following further incubation with a secondary peroxidase-conjugated antibody, the assay was developed by addition of a tetramethylbenzidine (TMB) chromogenic substrate. The reaction was terminated by addition of sulphuric acid and absorbance at 450 nm was determined using a microtitre plate reader. The linear standard curve was used to determine concentrations in positive control and test samples. Samples with concentrations exceeding the highest standard (19.3 ng/ml) were reanalysed using a further 5-fold sample dilution. 
